PA
CMPX icon

Parallel Advisors’s Compass Therapeutics CMPX Stock Holding History

Parallel Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.8K Buy
+5,250
New +$30.3K ﹤0.01% 2319

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Parallel Advisors's CMPX Position: Q1 2026 in Review

Parallel Advisors opened a new position in Compass Therapeutics (CMPX) in Q1 2026: 5,250 shares worth $27.8K. The stake represents ﹤0.01% of the portfolio and ranks #2319 among its holdings.

201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Parallel Advisors held 5,250 shares of Compass Therapeutics worth $27.8K as of Q1 2026.
  • Compass Therapeutics was a new Parallel Advisors position in Q1 2026.
  • Compass Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #2319 holding.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.